Such a regulation renders leukemia PDXs sensitive to the PI3Kγ inhibitor eganelisib, indicating a leukemia subset selectively addicted to PI3Kγ signaling potentially driven by innate inflammatory signaling and elevated PIK3R5. This evidence concerns the gene PIK3R5 and leukemia.